Nanomedicine and epigenetics: New alliances to increase the odds in pancreatic cancer survival
Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest cancers worldwide, primarily due to its robust desmoplastic stroma and immunosuppressive tumor microenvironment (TME), which facilitate tumor progression and metastasis. In addition, fibrous tissue leads to sparse vasculature, high inter...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-09-01
|
| Series: | Biomedicine & Pharmacotherapy |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0753332223009708 |
| _version_ | 1797744080697950208 |
|---|---|
| author | Maria Urbanova Marina Cihova Verona Buocikova Jan Slopovsky Peter Dubovan Daniel Pindak Miroslav Tomas Laura García-Bermejo Mercedes Rodríguez-Garrote Julie Earl Yvonne Kohl Agapi Kataki Maria Dusinska Bruno Sainz, Jr. Bozena Smolkova Alena Gabelova |
| author_facet | Maria Urbanova Marina Cihova Verona Buocikova Jan Slopovsky Peter Dubovan Daniel Pindak Miroslav Tomas Laura García-Bermejo Mercedes Rodríguez-Garrote Julie Earl Yvonne Kohl Agapi Kataki Maria Dusinska Bruno Sainz, Jr. Bozena Smolkova Alena Gabelova |
| author_sort | Maria Urbanova |
| collection | DOAJ |
| description | Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest cancers worldwide, primarily due to its robust desmoplastic stroma and immunosuppressive tumor microenvironment (TME), which facilitate tumor progression and metastasis. In addition, fibrous tissue leads to sparse vasculature, high interstitial fluid pressure, and hypoxia, thereby hindering effective systemic drug delivery and immune cell infiltration. Thus, remodeling the TME to enhance tumor perfusion, increase drug retention, and reverse immunosuppression has become a key therapeutic strategy. In recent years, targeting epigenetic pathways has emerged as a promising approach to overcome tumor immunosuppression and cancer progression. Moreover, the progress in nanotechnology has provided new opportunities for enhancing the efficacy of conventional and epigenetic drugs. Nano-based drug delivery systems (NDDSs) offer several advantages, including improved drug pharmacokinetics, enhanced tumor penetration, and reduced systemic toxicity. Smart NDDSs enable precise targeting of stromal components and augment the effectiveness of immunotherapy through multiple drug delivery options. This review offers an overview of the latest nano-based approaches developed to achieve superior therapeutic efficacy and overcome drug resistance. We specifically focus on the TME and epigenetic-targeted therapies in the context of PDAC, discussing the advantages and limitations of current strategies while highlighting promising new developments. By emphasizing the immense potential of NDDSs in improving therapeutic outcomes in PDAC, our review paves the way for future research in this rapidly evolving field. |
| first_indexed | 2024-03-12T15:04:36Z |
| format | Article |
| id | doaj.art-a631f60bbe0d4a01bd258ba8e15d01e8 |
| institution | Directory Open Access Journal |
| issn | 0753-3322 |
| language | English |
| last_indexed | 2024-03-12T15:04:36Z |
| publishDate | 2023-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Biomedicine & Pharmacotherapy |
| spelling | doaj.art-a631f60bbe0d4a01bd258ba8e15d01e82023-08-13T04:52:53ZengElsevierBiomedicine & Pharmacotherapy0753-33222023-09-01165115179Nanomedicine and epigenetics: New alliances to increase the odds in pancreatic cancer survivalMaria Urbanova0Marina Cihova1Verona Buocikova2Jan Slopovsky3Peter Dubovan4Daniel Pindak5Miroslav Tomas6Laura García-Bermejo7Mercedes Rodríguez-Garrote8Julie Earl9Yvonne Kohl10Agapi Kataki11Maria Dusinska12Bruno Sainz, Jr.13Bozena Smolkova14Alena Gabelova15Department of Molecular Oncology, Cancer Research Institute, Biomedical Research Center of the Slovak Academy of Sciences, Dubravska Cesta 9, 845 05 Bratislava, SlovakiaDepartment of Molecular Oncology, Cancer Research Institute, Biomedical Research Center of the Slovak Academy of Sciences, Dubravska Cesta 9, 845 05 Bratislava, SlovakiaDepartment of Molecular Oncology, Cancer Research Institute, Biomedical Research Center of the Slovak Academy of Sciences, Dubravska Cesta 9, 845 05 Bratislava, Slovakia2nd Department of Oncology, National Cancer Institute, Klenova 1, 833 10 Bratislava, Slovakia; Faculty of Medicine, Comenius University, Spitalska 24, 813 72 Bratislava, SlovakiaDepartment of Molecular Oncology, Cancer Research Institute, Biomedical Research Center of the Slovak Academy of Sciences, Dubravska Cesta 9, 845 05 Bratislava, Slovakia; Department of Surgical Oncology, National CancerInstitute in Bratislava, Klenova 1, 833 10 Bratislava, Slovakia; Faculty of Medicine, Slovak Medical University in Bratislava, Limbová12, 833 03 BratislavaDepartment of Surgical Oncology, National CancerInstitute in Bratislava, Klenova 1, 833 10 Bratislava, Slovakia; Faculty of Medicine, Slovak Medical University in Bratislava, Limbová12, 833 03 BratislavaDepartment of Molecular Oncology, Cancer Research Institute, Biomedical Research Center of the Slovak Academy of Sciences, Dubravska Cesta 9, 845 05 Bratislava, Slovakia; Department of Surgical Oncology, National CancerInstitute in Bratislava, Klenova 1, 833 10 Bratislava, Slovakia; Faculty of Medicine, Slovak Medical University in Bratislava, Limbová12, 833 03 BratislavaBiomarkers and Therapeutic Targets Group, Area4, Ramón y Cajal Health Research Institute (IRYCIS), Carretera Colmenar Km 9100, 28034 Madrid, SpainMolecular Epidemiology and Predictive Tumor Markers Group, Area 3, Ramón y Cajal Health Research Institute (IRYCIS), Carretera Colmenar Km 9100, 28034 Madrid, Spain; CIBERONC, Madrid, SpainMolecular Epidemiology and Predictive Tumor Markers Group, Area 3, Ramón y Cajal Health Research Institute (IRYCIS), Carretera Colmenar Km 9100, 28034 Madrid, Spain; CIBERONC, Madrid, SpainDepartment Bioprocessing & Bioanalytics, Fraunhofer Institute for Biomedical Engineering IBMT, 66280 Sulzbach, Germany1st Department of Propaedeutic Surgery, National and Kapodistrian University of Athens, Vasilissis Sofias 114, 11527 Athens, GreeceHealth Effects Laboratory, Department of Environmental Chemistry, NILU-Norwegian Institute for Air Research, Instituttveien 18, 2002 Kjeller, NorwayCIBERONC, Madrid, Spain; Instituto de Investigaciones Biomédicas''Alberto Sols'' (IIBM), CSIC-UAM, 28029 Madrid, Spain; Biomarkers and Personalized Approach to Cancer (BIOPAC) Group, Area 3, Ramón y Cajal Health Research Institute (IRYCIS), 28034 Madrid, SpainDepartment of Molecular Oncology, Cancer Research Institute, Biomedical Research Center of the Slovak Academy of Sciences, Dubravska Cesta 9, 845 05 Bratislava, SlovakiaDepartment of Nanobiology, Cancer Research Institute, Biomedical Research Center of the Slovak Academy of Sciences, Dubravska Cesta 9, 84505 Bratislava, Slovakia.; Correspondence to: Cancer Research Institute, Biomedical Research Center of the Slovak Academy of Sciences, Dubravska Cesta 9, 845 05 Bratislava, Slovakia.Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest cancers worldwide, primarily due to its robust desmoplastic stroma and immunosuppressive tumor microenvironment (TME), which facilitate tumor progression and metastasis. In addition, fibrous tissue leads to sparse vasculature, high interstitial fluid pressure, and hypoxia, thereby hindering effective systemic drug delivery and immune cell infiltration. Thus, remodeling the TME to enhance tumor perfusion, increase drug retention, and reverse immunosuppression has become a key therapeutic strategy. In recent years, targeting epigenetic pathways has emerged as a promising approach to overcome tumor immunosuppression and cancer progression. Moreover, the progress in nanotechnology has provided new opportunities for enhancing the efficacy of conventional and epigenetic drugs. Nano-based drug delivery systems (NDDSs) offer several advantages, including improved drug pharmacokinetics, enhanced tumor penetration, and reduced systemic toxicity. Smart NDDSs enable precise targeting of stromal components and augment the effectiveness of immunotherapy through multiple drug delivery options. This review offers an overview of the latest nano-based approaches developed to achieve superior therapeutic efficacy and overcome drug resistance. We specifically focus on the TME and epigenetic-targeted therapies in the context of PDAC, discussing the advantages and limitations of current strategies while highlighting promising new developments. By emphasizing the immense potential of NDDSs in improving therapeutic outcomes in PDAC, our review paves the way for future research in this rapidly evolving field.http://www.sciencedirect.com/science/article/pii/S0753332223009708Pancreatic ductal adenocarcinomaTumor microenvironmentEpigeneticsNanomedicine immunosuppression |
| spellingShingle | Maria Urbanova Marina Cihova Verona Buocikova Jan Slopovsky Peter Dubovan Daniel Pindak Miroslav Tomas Laura García-Bermejo Mercedes Rodríguez-Garrote Julie Earl Yvonne Kohl Agapi Kataki Maria Dusinska Bruno Sainz, Jr. Bozena Smolkova Alena Gabelova Nanomedicine and epigenetics: New alliances to increase the odds in pancreatic cancer survival Biomedicine & Pharmacotherapy Pancreatic ductal adenocarcinoma Tumor microenvironment Epigenetics Nanomedicine immunosuppression |
| title | Nanomedicine and epigenetics: New alliances to increase the odds in pancreatic cancer survival |
| title_full | Nanomedicine and epigenetics: New alliances to increase the odds in pancreatic cancer survival |
| title_fullStr | Nanomedicine and epigenetics: New alliances to increase the odds in pancreatic cancer survival |
| title_full_unstemmed | Nanomedicine and epigenetics: New alliances to increase the odds in pancreatic cancer survival |
| title_short | Nanomedicine and epigenetics: New alliances to increase the odds in pancreatic cancer survival |
| title_sort | nanomedicine and epigenetics new alliances to increase the odds in pancreatic cancer survival |
| topic | Pancreatic ductal adenocarcinoma Tumor microenvironment Epigenetics Nanomedicine immunosuppression |
| url | http://www.sciencedirect.com/science/article/pii/S0753332223009708 |
| work_keys_str_mv | AT mariaurbanova nanomedicineandepigeneticsnewalliancestoincreasetheoddsinpancreaticcancersurvival AT marinacihova nanomedicineandepigeneticsnewalliancestoincreasetheoddsinpancreaticcancersurvival AT veronabuocikova nanomedicineandepigeneticsnewalliancestoincreasetheoddsinpancreaticcancersurvival AT janslopovsky nanomedicineandepigeneticsnewalliancestoincreasetheoddsinpancreaticcancersurvival AT peterdubovan nanomedicineandepigeneticsnewalliancestoincreasetheoddsinpancreaticcancersurvival AT danielpindak nanomedicineandepigeneticsnewalliancestoincreasetheoddsinpancreaticcancersurvival AT miroslavtomas nanomedicineandepigeneticsnewalliancestoincreasetheoddsinpancreaticcancersurvival AT lauragarciabermejo nanomedicineandepigeneticsnewalliancestoincreasetheoddsinpancreaticcancersurvival AT mercedesrodriguezgarrote nanomedicineandepigeneticsnewalliancestoincreasetheoddsinpancreaticcancersurvival AT julieearl nanomedicineandepigeneticsnewalliancestoincreasetheoddsinpancreaticcancersurvival AT yvonnekohl nanomedicineandepigeneticsnewalliancestoincreasetheoddsinpancreaticcancersurvival AT agapikataki nanomedicineandepigeneticsnewalliancestoincreasetheoddsinpancreaticcancersurvival AT mariadusinska nanomedicineandepigeneticsnewalliancestoincreasetheoddsinpancreaticcancersurvival AT brunosainzjr nanomedicineandepigeneticsnewalliancestoincreasetheoddsinpancreaticcancersurvival AT bozenasmolkova nanomedicineandepigeneticsnewalliancestoincreasetheoddsinpancreaticcancersurvival AT alenagabelova nanomedicineandepigeneticsnewalliancestoincreasetheoddsinpancreaticcancersurvival |